| Xiangyu Meng,Xiaoping Liu,Chunrui Li,Cheng Fang,Li He. IGIACP1 predicts the prognosis in multiple myeloma patients. Oncol Transl Med, 2017, 3: 217-220. |
| ACP1预测多发性骨髓瘤患者预后 |
| IGIACP1 predicts the prognosis in multiple myeloma patients |
| Received:August 07, 2017 Revised:September 08, 2017 |
| DOI：10.1007/s10330-016-0238-8 |
| 中文关键词: 多发性骨髓瘤；预后；ACP1；LMW-PTP |
| 英文关键词: multiple myeloma; prognosis; ACP1; low-molecular-weight protein tyrosine phosphatase (LMWPTP) |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Xiangyu Meng | Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China | mengxy_whu@163.com | | Xiaoping Liu | Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China | | | Chunrui Li | Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China | | | Cheng Fang | Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China | | | Li He* | Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China | lihe_whu@163.com |
|
| Hits: 8886 |
| Download times: 10488 |
| 中文摘要: |
| 摘要
目的：使用GEO数据集探究ACP1表达在多发性骨髓瘤患者中的预后价值。资料与方法：系统检索GEO数据库以发现可用于分析的数据集。自涉及初治和复发骨髓瘤患者的数据集提取ACP1的表达水平数据并进行比较。为分析ACP1的预后作用，提取临床随访资料和ACP1表达数据，以总生存为结局指标对高表达组（≥75百分位数）和低表达组（≤25百分位数）的生存情况进行比较。结果：使用GSE6477数据集比较初治骨髓瘤患者与复发骨髓瘤患者的ACP1的表达情况。结果显示，复发患者的ACP1平均表达水平显著高于初治患者（均数差=-262.9, 95%可信区间 = [-420.2, -105.5]，P = 0.002）。使用GSE 2658数据集分析ACP1在骨髓瘤患者的预后预测价值。结果显示，ACP1高表达组的总生存显著劣于低表达组（HR = 0.54，95%可信区间= [0.31, 0.95]，P = 0.0314）。结论：我们的研究首次发现ACP1能够预测骨髓瘤患者预后。后续研究应着眼于探究其机制，尤其是LMW-PTP同工型的不同作用。 |
| 英文摘要: |
| Objective The aim of this study was to investigate the prognostic relevance of acid phosphatase 1
(ACP1) expression in myeloma patients by using Gene Expression Omnibus (GEO) datasets.
Methods A comprehensive search was performed in the GEO database in order to find appropriate
datasets. The expression level of ACP1 was extracted from the dataset involving both newly diagnosed
and relapsed myeloma patients, and a comparison was made. Clinical follow-up data and ACP1 expression
were extracted, and survival analysis of overall survival was performed to compare the high- (top quartile)
and low-expression (bottom quartile) groups. Analyses using Kaplan-Meier estimation, log-rank test, and
restricted mean survival time (RMST) comparison were performed.
Results The GSE 6477 dataset was used to make a comparison of the ACP1 expression levels among
patients with newly diagnosed and relapsed myeloma. The ACP1 expression level was significantly higher
in the relapsed group than in the newly diagnosed group [mean difference = -262.9, 95% confidence
interval (CI) = (-420.2, -105.5), P = 0.002]. The GSE 2658 dataset was used for investigating the prognostic
relevance of ACP1 expression in myeloma. The ACP1 high-expression group had a significantly worse
prognosis [low vs high: hazard ratio = 0.54, 95% CI = (0.31, 0.95); χ2 = 5.02, log rank P = 0.0314]. The
median survival was 55.9 months in the high-expression group and was not reached in the low-expression
group. The restricted mean time loss (95% CI) was 11.03 (12.97, 23.11) and 18.04 (12.97, 23.11) for the
low- and high-expression groups, respectively. The ratio of RMST (95% CI) between the two groups (high
vs low) was 0.87 (0.77, 0.99; P = 0.03).
Conclusion Our study, for the first time, showed that ACP1 predicts the prognosis in multiple myeloma
patients. Further studies are needed to determine the potential mechanism by which ACP1 is associated
with clinical outcomes and should focus on the differential roles of low-molecular-weight protein tyrosine
phosphatase (LMWPTP) isoforms. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|